BACKGROUND: Risk of recurrent @entity65 following an initial cardiovascular-related hospitalization remains high despite available interventions. Rates of @entity65 as well as associated health care resource utilization and costs are needed to assess the value of treatments. OBJECTIVE: To quantify, in @entity1 with previous hospitalization for @entity1187 ( @entity1187 ), rates of nonfatal major adverse @entity65 (MACE) and secondary coronary events (SCE), as well as health care utilization and costs associated with a first MACE. METHODS: Administrative data from a large population of commercial managed care and managed Medicare enrollees in the United States were retrospectively analyzed. @entity1 with an @entity1187 -related hospitalization from 2006 to 2011 were followed for 12 months to assess subsequent MACE and SCE rates. @entity1 were aged >=  18 years at initial @entity1187 hospitalization (the index episode) and had >=  12 months of continuous health plan enrollment before and after the end of the index episode. Resource utilization and costs during a first MACE were assessed. Multivariable analyses were used to assess the associations between cardiovascular risk factors and the occurrence of a MACE, as well as the costs incurred during a first MACE. RESULTS: Of 75,231 study @entity1 identified, 3.3% had a MACE and 8.3% had an SCE during the 12-month follow-up. Median time to first MACE and SCE from end of the index episode was 4.6 and 3.7 months, respectively. Mean MACE-related cost incurred during the first MACE was  19,642. Logistic analyses showed that age and @entity6 were associated with increased odds of a MACE, while index @entity1187 episodes involving @entity583 were associated with reduced odds. Findings from generalized linear models indicated that @entity6817 use and age were associated with lower episode-related costs and that MACE occurrence within 3 months of @entity1187 hospitalization was associated with increased episode-related costs. CONCLUSIONS: MACEs and SCEs represent a common and costly burden in the year following @entity1187 hospitalization. Our findings may inform future economic assessments of new therapies aimed at prevention of MACEs and SCEs.

Health care resource utilization and costs associated with nonfatal major adverse XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity6817 :: ('D019821', 'Chemical') :: ['statin'] @entity583 :: ('MESH:D009203', 'Disease') :: ['ST-elevation myocardial infarction'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular events']
@entity65 :: (MESH:D002318,Disease) :: ['cardiovascular events']
